{"id":"W2117985979","doi":"10.1093/annonc/mds503","title":"A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); University of Toronto; Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Hôpital Notre-Dame","funders":"Pfizer","keywords":"Medicine; Discontinuation; Internal medicine; Clinical endpoint; Adverse effect; Mucositis; Phases of clinical research; Gastroenterology; Toxicity; Response Evaluation Criteria in Solid Tumors; Oncology; Diarrhea; Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001652963,0.001789754,0.002768755,0.0005244214,0.0005097677,0.001274523,0.00104383,0.001667196,0.005304788],"category_scores_gemma":[0.001221946,0.0006506224,0.001520653,0.0005570918,0.001114217,0.001302354,0.0003328917,0.004848289,0.001178198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00121867,"about_ca_system_score_gemma":0.00168237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002058834,"about_ca_topic_score_gemma":0.007232756,"domain_scores_codex":[0.9996717,0.000131496,0.00001417127,0.00006923598,0.00002793164,0.00008551696],"domain_scores_gemma":[0.9992823,0.0001347861,0.00007287438,0.00005335032,0.00003794641,0.0004187217],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8254262,0.04064098,0.003966376,0.001233011,0.001638362,0.000300047,0.000309019,0.002822881,0.0194479,0.00053597,0.01099431,0.09268507],"study_design_scores_gemma":[0.8458637,0.1430127,0.004995167,0.00003858033,0.0004163,0.0002718594,0.00008155454,0.001028914,0.001230506,0.000269214,0.002761852,0.00002959772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814208,0.006157469,0.0005345944,0.001618246,0.0007580852,0.002431574,0.002386103,0.0001571555,0.004536027],"genre_scores_gemma":[0.9764428,0.005597578,0.001765602,0.002109039,0.0003834557,0.002226756,0.004971612,0.00006340782,0.006439834],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005304788,"threshold_uncertainty_score":0.01774627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1637312590794041,"score_gpt":0.4497710802575013,"score_spread":0.2860398211780972,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}